Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open, exploratory clinical study to evaluate the efficacy and safety of
camrelizumab combined with chemotherapy for adjuvant treatment of nodal positive thoracic
esophageal squamous cell carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital